Daiichi Sankyo begins phase 3 trial of mRNA Covid-19 vaccine, DS-5670) in unvaccinated individuals in Japan

Daiichi Sankyo announced that it has initiated a phase 3 trial of DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (Covid-19), in healthy unvaccinated adults. The trial is an active-controlled, trial to investigate the non-inferiority of DS-5670 to an already-approved mRNA vaccine (Comirnaty) in terms of immunogenicity and seroconversion rate in 322 healthy adults in Japan who have not yet received a Covid-19 vaccine or been infected with the novel coronavirus. As a Japanese pharmaceutical company with specialty in developing vaccines, Daiichi Sankyo is proceeding with the development of DS-5670 and will continue consultation with regulatory authorities to deliver a domestically produced mRNA vaccine to people in Japan as soon as possible. DS-5670 is an mRNA vaccine against Covid-19 using a cationic lipid discovered by Daiichi Sankyo, designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus, and thus expected to have desirable efficacy and safety. In addition, DS-5670 in animal models induced neutralizing activities against the omicron variant to a certain extent following the initial vaccination. The clinical development of DS-5670 is being conducted through

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!